pramipexole has been researched along with oxidopamine in 30 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | pramipexole (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 8 (26.67) | 29.6817 |
| 2010's | 17 (56.67) | 24.3611 |
| 2020's | 4 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fibiger, HC; Jakubovic, A; Robertson, GS; Tham, CS; Wilson, C | 1 |
| Carvey, PM; Chen, EY; Ling, ZD; Lipton, JW; Ma, SY; Robie, HC; Tong, CW; Vu, TQ | 1 |
| Ferger, B; Mierau, J; Teismann, P | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Appel, SH; Jankovic, J; Le, WD; Xie, W | 1 |
| Albin, RL; Desmond, TJ; Frey, KA; Kemmerer, ES; Kilbourn, MR | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Ogawa, N; Shimizu, M; Tanaka, K | 1 |
| Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR | 1 |
| Aigner, L; Aigner, R; Buerger, E; Desplats, P; Hagl, C; Karl, A; Klucken, J; Laemke, J; Masliah, E; Ploetz, S; Winkler, J; Winner, B | 1 |
| de Mello, MT; Esteves, AM; Frussa-Filho, R; Lopes, C; Tufik, S | 1 |
| Napier, TC; Rokosik, SL | 1 |
| Napier, TC; Riddle, JL; Rokosik, SL | 1 |
| Ahmed, SH; Bezard, E; Engeln, M; Fernagut, PO; Tison, F; Vouillac, C | 1 |
| Bagetta, V; Calabresi, P; Del Papa, G; Gardoni, F; Ghiglieri, V; Giampà, C; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A; Zianni, E | 1 |
| Bonastre, M; Cortés, R; Giralt, A; Marin, C; Mengod, G; Obeso, JA; Schapira, AH | 1 |
| Berghauzen-Maciejewska, K; Dziubina, A; Głowacka, U; Kolasiewicz, W; Kuter, K; Ossowska, K; Wardas, J | 1 |
| Cho, JH; Kim, GS; Kim, MK; Park, HS; Won, C | 1 |
| Berghauzen-Maciejewska, K; Głowacka, U; Kosmowska, B; Kuter, K; Ossowska, K; Wardas, J | 1 |
| Chiu, WH; Depboylu, C; Hermanns, G; Höglinger, GU; Maurer, L; Oertel, WH; Ries, V; Windolph, A | 1 |
| Fernández, E; Fresno, C; Gershanik, OS; Gomez, G; González, GA; Larramendy, C; Murer, MG; Saborido, MD; Spaans, F; Taravini, IR | 1 |
| Hiratochi, M; Ijiro, T; Kaidoh, K; Oana, F; Suzuki, T; Tsuchioka, A; Yamauchi, Y | 1 |
| Berghauzen-Maciejewska, K; Domin, H; Głowacka, U; Kosmowska, B; Ossowska, K; Śmiałowska, M; Wardas, J | 1 |
| Grasso, SA; Holtz, NA; Napier, TC; Persons, AL; Tedford, SE | 1 |
| Di Chiara, G; Espa, E; Fenu, S; Pisanu, A | 1 |
| Chassain, C; Dardou, D; Durif, F; Reyrolle, L | 1 |
| Aguilera, J; Limón, ID; Martínez, I; Mendieta, L; Montes, S; Parra, I; Patricio, F; Pérez-Severiano, F; Tizabi, Y | 1 |
| Austrich-Olivares, AM; Benitez-Diaz Mirón, M; Coen, A; Garza-Mouriño, G; Godínez-Chaparro, B; Mendieta, L; Romero-Sánchez, HA | 1 |
| Belloso-Iguerategui, A; Delgado-Alvarado, M; Gago, B; Jiménez-Urbieta, H; Marin, C; Merino-Galán, L; Navalpotro-Gómez, I; Quiroga-Varela, A; Rodríguez-Chinchilla, T; Rodríguez-Oroz, MC | 1 |
| Bonastre, M; Fuentes, M; Marin, C; Mullol, J | 1 |
| Gao, H; Jiang, S; Mao, JP; Wang, D; Wang, YL; Yang, XL | 1 |
30 other study(ies) available for pramipexole and oxidopamine
| Article | Year |
|---|---|
In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release.
Topics: Acetylcholine; Animals; Azepines; Benzothiazoles; Corpus Striatum; Dopamine; Dopamine Agents; Ergolines; Male; Oxidopamine; Pramipexole; Quinpirole; Raclopride; Rats; Rats, Wistar; Receptors, Dopamine; Salicylamides; Thiazoles | 1993 |
Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine.
Topics: Animals; Benzothiazoles; Cell Count; Cell Death; Dopamine; Dopamine Agonists; Male; Neostriatum; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles | 2000 |
The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study.
Topics: Adrenergic Agents; Animals; Benzothiazoles; Corpus Striatum; Dopamine; Dopamine Agonists; Hydroxybenzoates; Hydroxyl Radical; Male; Microdialysis; Oxidopamine; Pergolide; Pramipexole; Rats; Rats, Wistar; Thiazoles | 2000 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles | 2000 |
Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.
Topics: Animals; Antioxidants; Benzothiazoles; Cell Line; Cell Survival; Dopamine; Dopamine D2 Receptor Antagonists; Hydrogen Peroxide; Neurons; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Pramipexole; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3; Thiazoles | 2000 |
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothiazoles; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles; Treatment Outcome; Tritium; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; Benzothiazoles; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electron Spin Resonance Spectroscopy; Functional Laterality; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinson Disease; Pramipexole; Thiazoles; Time Factors | 2005 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2008 |
Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model.
Topics: Animals; Benzothiazoles; Bromodeoxyuridine; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dopamine Agonists; ErbB Receptors; Exploratory Behavior; Eye Proteins; Functional Laterality; Gene Expression Regulation; Homeodomain Proteins; Lateral Ventricles; Male; Neurogenesis; Neurons; Olfactory Bulb; Oxidopamine; Paired Box Transcription Factors; Parkinsonian Disorders; PAX6 Transcription Factor; Phosphopyruvate Hydratase; Pramipexole; Proliferating Cell Nuclear Antigen; Rats; Rats, Inbred F344; Receptors, Dopamine D2; Receptors, Dopamine D3; Repressor Proteins; RNA, Messenger | 2009 |
Evaluation of periodic limb movements in a putative animal model of restless leg syndrome.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benzothiazoles; Disease Models, Animal; Electroencephalography; Electromyography; Extremities; Male; Movement; Nocturnal Myoclonus Syndrome; Oxidopamine; Pramipexole; Rats; Rats, Wistar; Restless Legs Syndrome; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2012 |
Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benzothiazoles; Biophysics; Conditioning, Operant; Disease Models, Animal; Disruptive, Impulse Control, and Conduct Disorders; Electric Stimulation; Electrodes, Implanted; Male; Motor Activity; Oxidopamine; Parkinson Disease; Pramipexole; Probability Learning; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Risk-Taking; Self Administration | 2012 |
Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Association Learning; Benzothiazoles; Conditioning, Operant; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Forelimb; Male; Methamphetamine; Motor Activity; Nucleus Accumbens; Oxidopamine; Parkinson Disease; Pramipexole; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Reward; Tyrosine 3-Monooxygenase | 2012 |
Reinforcing properties of Pramipexole in normal and parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Drug-Seeking Behavior; Extinction, Psychological; Immunohistochemistry; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-fos; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Reinforcement Schedule; Self Administration; Substance-Related Disorders | 2013 |
Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate | 2012 |
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Benserazide; Benzothiazoles; Corpus Striatum; Hippocampus; Levodopa; Male; Motor Activity; Neurogenesis; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Substantia Nigra; Time Factors | 2014 |
Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
Topics: Animals; Antidepressive Agents; Benzothiazoles; Depression; Disease Models, Animal; Dopamine Agonists; Fluoxetine; Imipramine; Male; Motor Activity; Oxidopamine; Parkinson Disease; Pramipexole; Rats; Rats, Wistar; Swimming; Treatment Outcome | 2014 |
Pramipexole protects dopaminergic neurons through paraplegin against 6-hydroxydopamine.
Topics: Animals; ATPases Associated with Diverse Cellular Activities; Benzothiazoles; Cells, Cultured; Dopamine Agonists; Dopaminergic Neurons; Metalloendopeptidases; Mice; Mice, Inbred ICR; Nerve Degeneration; Neuroprotective Agents; Oxidopamine; Pramipexole; Receptors, Dopamine D2; Signal Transduction | 2015 |
Alterations of BDNF and trkB mRNA expression in the 6-hydroxydopamine-induced model of preclinical stages of Parkinson's disease: an influence of chronic pramipexole in rats.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Brain; Brain-Derived Neurotrophic Factor; Male; Oxidopamine; Parkinson Disease; Pramipexole; Rats; Rats, Wistar; Receptor, trkB; RNA, Messenger | 2015 |
Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Anxiety; Benzothiazoles; Depression; Hippocampus; Levodopa; Male; Mice, Inbred C57BL; Neurogenesis; Neurons; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation | 2015 |
Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzothiazoles; Cluster Analysis; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Levodopa; Male; Microarray Analysis; Oxidopamine; Parkinson Disease; Pramipexole; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2016 |
Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions.
Topics: Animals; Antiparkinson Agents; Apomorphine; Azepines; Benzothiazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Ergolines; Indoles; Injections, Intraventricular; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Quinolines; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 2015 |
Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson's disease and after chronic pramipexole treatment.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Brain; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Dorsal Raphe Nucleus; Down-Regulation; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Pramipexole; Radionuclide Imaging; Rats; Rats, Wistar; Serotonergic Neurons; Serotonin Plasma Membrane Transport Proteins; Tryptophan Hydroxylase; Tyrosine 3-Monooxygenase | 2016 |
Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.
Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Benzothiazoles; Corpus Striatum; Delay Discounting; Dopamine Agonists; Dose-Response Relationship, Drug; Impulsive Behavior; Male; Mianserin; Mirtazapine; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation; Rats, Sprague-Dawley; Risk-Taking; Self Stimulation | 2016 |
In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.
Topics: Animals; Behavior, Animal; Benzothiazoles; Dopamine; Dopamine Agonists; Gene Expression Regulation; Male; Oxidopamine; Pramipexole; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 2016 |
Chronic pramipexole treatment induces compulsive behavior in rats with 6-OHDA lesions of the substantia nigra and ventral tegmental area.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Compulsive Behavior; Corpus Striatum; Frontal Lobe; Immunohistochemistry; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Substantia Nigra; Ventral Tegmental Area | 2017 |
Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Antiparkinson Agents; Astrocytes; Corpus Striatum; Drug Therapy, Combination; Gliosis; Male; Microglia; Motor Activity; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Peptide Fragments; Pramipexole; Random Allocation; Rats, Wistar; Tetanus Toxin; Time Factors | 2019 |
Unilateral lesion of the nigroestriatal pathway with 6-OHDA induced allodynia and hyperalgesia reverted by pramipexol in rats.
Topics: Analgesics; Animals; Antiparkinson Agents; Dopamine Agonists; Hyperalgesia; Male; Oxidopamine; Pars Compacta; Pramipexole; Rats, Wistar; Touch | 2020 |
Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats.
Topics: Animals; Corpus Striatum; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Impulsive Behavior; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley | 2020 |
Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Pramipexole; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2020 |
Pramipexole attenuates 6-OHDA-induced Parkinson's disease by mediating the Nurr1/NF-κB pathway.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Disease Models, Animal; NF-kappa B; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinson Disease; Pramipexole; Rats; Signal Transduction | 2021 |